Investor Relations

Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

Read Press Release

Latest Financial Results

2020

Year End Results

Ended Dec 31, 2020

Stock Information

Symbol NYSE American: OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Company Overview

Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.

Contact Information

Investor Relations
LHA Investor Relations
Kim Golodetz
Senior Vice President, Principal
T: 212-838-3777
kgolodetz@lhai.com

Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000